Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland L Dunbrack

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Science Advances|April 8, 2021
Structure of TFIIK for phosphorylation of CTD of RNA polymerase IITrevor van Eeuwen, Tao Li, Hee Jong Kim, et al.
Cancer Biology & Therapy|May 12, 2017
Functional analysis of rare variants in mismatch repair proteins augments results from computation-based predictive methodsSanjeevani Arora, Peter J Huwe, Rahmat Sikder, et al.
Heliyon|September 13, 2023
Corrigendum to "Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus" [Heliyon 9(4) (April 2023) e15032]Nancy E Hernandez, Wojciech Jankowski, Rahel Frick, et al.
Human Mutation|April 4, 2017
Benchmarking predictions of allostery in liver pyruvate kinase in CAGI4Qifang Xu, Qingling Tang, Panagiotis Katsonis, et al.
Heliyon|April 10, 2023
Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virusNancy E Hernandez, Wojciech Jankowski, Rahel Frick, et al.
Molecular Cancer Research : MCR|January 11, 2013
A modified HSP70 inhibitor shows broad activity as an anticancer agentGregor M Balaburski, Julia I-Ju Leu, Neil Beeharry, et al.
Nature Communications|June 13, 2024
E proteins control the development of NKγδT cells through their invariant T cell receptorAriana Mihai, Sang-Yun Lee, Susan Shinton, et al.
Oncotarget|June 8, 2017
BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutationsSafoora Deihimi, Avital Lev, Michael Slifker, et al.
Cancer Research Communications|January 29, 2024
Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor MutagenicityShreya M Shah, Elena V Demidova, Salena Ringenbach, et al.
Cancer Research Communications|May 31, 2024
Correction: Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor MutagenicityShreya M Shah, Elena V Demidova, Salena Ringenbach, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Science Advances|April 8, 2021
Structure of TFIIK for phosphorylation of CTD of RNA polymerase IITrevor van Eeuwen, Tao Li, Hee Jong Kim, et al.
Cancer Biology & Therapy|May 12, 2017
Functional analysis of rare variants in mismatch repair proteins augments results from computation-based predictive methodsSanjeevani Arora, Peter J Huwe, Rahmat Sikder, et al.
Heliyon|September 13, 2023
Corrigendum to "Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus" [Heliyon 9(4) (April 2023) e15032]Nancy E Hernandez, Wojciech Jankowski, Rahel Frick, et al.
Human Mutation|April 4, 2017
Benchmarking predictions of allostery in liver pyruvate kinase in CAGI4Qifang Xu, Qingling Tang, Panagiotis Katsonis, et al.
Heliyon|April 10, 2023
Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virusNancy E Hernandez, Wojciech Jankowski, Rahel Frick, et al.
Molecular Cancer Research : MCR|January 11, 2013
A modified HSP70 inhibitor shows broad activity as an anticancer agentGregor M Balaburski, Julia I-Ju Leu, Neil Beeharry, et al.
Nature Communications|June 13, 2024
E proteins control the development of NKγδT cells through their invariant T cell receptorAriana Mihai, Sang-Yun Lee, Susan Shinton, et al.
Oncotarget|June 8, 2017
BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutationsSafoora Deihimi, Avital Lev, Michael Slifker, et al.
Cancer Research Communications|January 29, 2024
Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor MutagenicityShreya M Shah, Elena V Demidova, Salena Ringenbach, et al.
Cancer Research Communications|May 31, 2024
Correction: Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor MutagenicityShreya M Shah, Elena V Demidova, Salena Ringenbach, et al.
Pageof 12